PURPOSE: To provide a Goodpasture's syndrome-treating agent containing 15- deoxyspagarin as an active ingredient, depressing both glomerular nephritis and pulmonary hemorrhage in the Goodpasture's syndrome and reduced in the adverse actions. ;CONSTITUTION: A new and highly safe therapeutic agent for the Goodpasture's syndrome contains 15-deoxyspagarin, i.e., 1-amino-19-guanidino-11-hydroxy-4,9,12- triazanonadecane-10,13-dione, as an active ingredient. The therapeutic agent is relatively low toxic and a little in the accumulation of toxicity caused by the continuous administration of this agent. The 15-deoxyspagarin is effective not only for the treatment of chronic nephritis but also for such other autoimmune diseases as causing progressive tissue atrophy due to sclerosis.;COPYRIGHT: (C)1993,JPO&Japio
展开▼
